Mouse Anti-PCLAF Recombinant Antibody (3C11-1F11) (CBMAB-K2189-LY)

Li, Y., Zeng, Z. W., Chen, D., Gu, Z. C., Yan, W. L., Yue, L. Y., ... & He, B. (2023). Facilitated Drug Repurposing with Artemisinin-Derived PROTACs: Unveiling PCLAF as a Therapeutic Target. Journal of Medicinal Chemistry, 66(16), 11335-11350.

Liu, L., Lv, Z., Wang, M., Zhang, D., Liu, D., & Zhu, F. (2023). HBV enhances sorafenib resistance in hepatocellular carcinoma by reducing ferroptosis via SRSF2-mediated abnormal PCLAF splicing. International Journal of Molecular Sciences, 24(4), 3263.

Liu, X., Cheng, C., Cai, Y., Gu, Y., Wu, Y., Chen, K., & Wu, Z. (2022). Pan‑cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors. International Journal of Oncology, 60(6), 1-13.

Liu, X., Cai, Y., Cheng, C., Gu, Y., Hu, X., Chen, K., ... & Wu, Z. (2022). PCLAF promotes neuroblastoma G1/S cell cycle progression via the E2F1/PTTG1 axis. Cell death & disease, 13(2), 178.

Kim, B., Huang, Y., Ko, K. P., Zhang, S., Zou, G., Zhang, J., ... & Park, J. I. (2022). PCLAF-DREAM Drives Alveolar Cell Plasticity for Lung Regeneration. bioRxiv, 2022-10.

Magallanes-Garza, G. I., Santuario-Facio, S. K., Lira-Albarrán, S., Varela-Varela, A. F., Cardona-Huerta, S., Ruiz-Flores, P., ... & Ortiz-Lopez, R. (2022). NUSAP1 and PCLAF (KIA0101) downregulation by neoadjuvant therapy is associated with better therapeutic outcomes and survival in breast cancer. Journal of Oncology, 2022(1), 6001947.

Pan, L., Sha, J., Lin, W., Wang, Y., Bian, T., & Guo, J. (2021). Curcumin inhibits prostate cancer progression by regulating the miR‑30a‑5p/PCLAF axis. Experimental and Therapeutic Medicine, 22(3), 1-8.

Tantiwetrueangdet, A., Panvichian, R., Sornmayura, P., Leelaudomlipi, S., & Macoska, J. A. (2021). PCNA-associated factor (KIAA0101/PCLAF) overexpression and gene copy number alterations in hepatocellular carcinoma tissues. BMC cancer, 21, 1-12.

Ma, F., Zhi, C., Wang, M., Li, T., Khan, S. A., Ma, Z., ... & Ji, T. (2020). Dysregulated NF-κB signal promotes the hub gene PCLAF expression to facilitate nasopharyngeal carcinoma proliferation and metastasis. Biomedicine & Pharmacotherapy, 125, 109905.

Zhao, H., Zhang, W., Lai, X., Zhu, H., Zhang, S., Wu, W., ... & Tan, J. (2019). MiR-30a-5p frequently downregulated in prostate cancer inhibits cell proliferation via targeting PCLAF. Artificial cells, nanomedicine, and biotechnology, 47(1), 278-289.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols